应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
SNDX Syndax Pharmaceuticals, Inc.
盘后交易 07-17 16:25:52 EDT
23.69
-1.12
-4.51%
盘后
23.69
+0.00
0.00%
16:03 EDT
最高
24.76
最低
23.44
成交量
133.49万
今开
24.45
昨收
24.81
日振幅
5.32%
总市值
20.13亿
流通市值
20.05亿
总股本
8,499万
成交额
3,184万
换手率
1.58%
流通股本
8,465万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Syndax Pharmaceuticals, Inc.盘中异动 股价大跌5.00%
自选股智能写手 · 00:48
Syndax Pharmaceuticals, Inc.盘中异动 股价大跌5.00%
Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.02%报22.19美元
自选股智能写手 · 07-10
Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.02%报22.19美元
Syndax Pharmaceuticals, Inc.盘中异动 下午盘大幅拉升5.11%报21.58美元
自选股智能写手 · 07-02
Syndax Pharmaceuticals, Inc.盘中异动 下午盘大幅拉升5.11%报21.58美元
Syndax Pharmaceuticals, Inc.盘中异动 下午盘快速拉升5.03%报20.24美元
自选股智能写手 · 06-22
Syndax Pharmaceuticals, Inc.盘中异动 下午盘快速拉升5.03%报20.24美元
Syndax Pharmaceuticals, Inc.盘中异动 快速上涨5.02%报20.29美元
自选股智能写手 · 06-13
Syndax Pharmaceuticals, Inc.盘中异动 快速上涨5.02%报20.29美元
Syndax Pharmaceuticals, Inc.盘中异动 早盘急速上涨5.14%报20.26美元
自选股智能写手 · 06-03
Syndax Pharmaceuticals, Inc.盘中异动 早盘急速上涨5.14%报20.26美元
Syndax Pharmaceuticals, Inc.2024财年第一财季实现净利润-72.40百万美元,同比减少76.03%
自选股智能写手 · 05-18
Syndax Pharmaceuticals, Inc.2024财年第一财季实现净利润-72.40百万美元,同比减少76.03%
Stifel:维持Syndax Pharmaceuticals(SNDX.US)评级,由买入调整至买入评级, 目标价由39.00美元调整至40.00美元。
智通财经 · 05-09
Stifel:维持Syndax Pharmaceuticals(SNDX.US)评级,由买入调整至买入评级, 目标价由39.00美元调整至40.00美元。
Syndax Pharmaceuticals, Inc.盘中异动 急速跳水5.00%报22.02美元
自选股智能写手 · 05-08
Syndax Pharmaceuticals, Inc.盘中异动 急速跳水5.00%报22.02美元
Syndax Pharmaceuticals Inc 预计每股亏损 98 美分 - 财报前瞻
Reuters · 05-03
Syndax Pharmaceuticals Inc 预计每股亏损 98 美分 - 财报前瞻
Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.02%报22.19美元
自选股智能写手 · 05-02
Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.02%报22.19美元
HC Wainwright & Co.:重申Syndax Pharmaceuticals(SNDX.US)评级,由买入调整至买入评级, 目标价41.00美元。
智通财经 · 04-26
HC Wainwright & Co.:重申Syndax Pharmaceuticals(SNDX.US)评级,由买入调整至买入评级, 目标价41.00美元。
Syndax Pharmaceuticals, Inc.盘中异动 大幅跳水5.09%
自选股智能写手 · 04-11
Syndax Pharmaceuticals, Inc.盘中异动 大幅跳水5.09%
美国研究综述-迪克体育用品、Nvidia、PVH
Reuters · 03-20
美国研究综述-迪克体育用品、Nvidia、PVH
Syndax Pharmaceuticals, Inc.盘中异动 临近午盘快速下跌5.06%报22.33美元
自选股智能写手 · 03-18
Syndax Pharmaceuticals, Inc.盘中异动 临近午盘快速下跌5.06%报22.33美元
Syndax Pharmaceuticals, Inc.盘中异动 股价大跌5.09%
自选股智能写手 · 03-15
Syndax Pharmaceuticals, Inc.盘中异动 股价大跌5.09%
Syndax Pharmaceuticals, Inc.2023财年实现净利润-2.09亿美元,同比减少40.27%
自选股智能写手 · 03-03
Syndax Pharmaceuticals, Inc.2023财年实现净利润-2.09亿美元,同比减少40.27%
Syndax Pharmaceuticals Inc盘中异动 临近收盘急速上涨5.02%
自选股智能写手 · 02-27
Syndax Pharmaceuticals Inc盘中异动 临近收盘急速上涨5.02%
Syndax Pharmaceuticals Inc 预计每股亏损 99 美分 - 财报前瞻
Reuters · 02-24
Syndax Pharmaceuticals Inc 预计每股亏损 99 美分 - 财报前瞻
Syndax Pharmaceuticals Inc盘中异动 股价大跌5.16%
自选股智能写手 · 02-13
Syndax Pharmaceuticals Inc盘中异动 股价大跌5.16%
暂无数据
公司概况
公司名称:
Syndax Pharmaceuticals, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Syndax Pharmaceuticals, Inc.于2005年10月11日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司,正在开发癌症疗法的创新管道。该公司正在开发revumenib,这是一种有效的、选择性的、menin-MLL结合相互作用的小分子抑制剂,用于治疗KMT2A重排或KMT2AR,也称为混合谱系白血病重排或MLLR,包括急性淋巴细胞白血病或ALL在内的急性白血病,以及急性髓细胞白血病或AML,以及necleophosmin 1,也称为NPM1,突变AML。
发行价格:
--
{"stockData":{"symbol":"SNDX","market":"US","secType":"STK","nameCN":"Syndax Pharmaceuticals, Inc. ","latestPrice":23.69,"timestamp":1721246400000,"preClose":24.81,"halted":0,"volume":1334892,"hourTrading":{"tag":"盘后","latestPrice":23.69,"preClose":23.69,"latestTime":"16:03 EDT","volume":34163,"amount":809324.749648,"timestamp":1721246610614},"delay":0,"floatShares":84647477,"shares":84987060,"eps":-3.242697,"marketStatus":"盘后交易","marketStatusCode":4,"change":-1.12,"latestTime":"07-17 16:25:52 EDT","open":24.45,"high":24.76,"low":23.44,"amount":31840826.464512,"amplitude":0.053204,"askPrice":24.16,"askSize":70,"bidPrice":23.74,"bidSize":337,"shortable":3,"etf":0,"ttmEps":-3.242697,"exchange":"NASDAQ","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1721260800000},"adr":0,"listingDate":1456981200000,"adjPreClose":24.81,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":24.46,"preClose":24.81,"latestTime":"09:29 EDT","volume":101,"amount":2471.689978,"timestamp":1721222999999},"postHourTrading":{"tag":"盘后","latestPrice":23.69,"preClose":23.69,"latestTime":"16:03 EDT","volume":34163,"amount":809324.749648,"timestamp":1721246610614},"volumeRatio":1.258065,"impliedVol":0.5345,"impliedVolPercentile":0.1389},"requestUrl":"/m/hq/s/SNDX/tweets","defaultTab":"tweets","newsList":[{"id":"2452216202","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452216202","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452216202?lang=zh_cn&edition=full","pubTime":"2024-07-18 00:48","pubTimestamp":1721234905,"startTime":"0","endTime":"0","summary":"北京时间2024年07月18日00时48分,Syndax Pharmaceuticals, Inc.股票出现波动,股价大幅跳水5.00%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为2.21%。其相关个股中,Aptevo Therapeutics Inc.、Geovax Labs Inc C/Wts 29/09/2025、Conduit Pharmaceuticals Inc C/Wts 22/09/2028涨幅较大,Aptevo Therapeutics Inc.、Aditxt, Inc.、Longeveron Inc.较为活跃,换手率分别为3323.58%、1382.05%、294.53%,振幅较大的相关个股有Aptevo Therapeutics Inc.、Aditxt, Inc.、4D Molecular Therapeutics, Inc.,振幅分别为76.39%、46.25%、45.71%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407180048259681db94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407180048259681db94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2450074235","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.02%报22.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450074235","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450074235?lang=zh_cn&edition=full","pubTime":"2024-07-10 03:22","pubTimestamp":1720552938,"startTime":"0","endTime":"0","summary":"北京时间2024年07月10日03时22分,Syndax Pharmaceuticals, Inc.股票出现波动,股价大幅上涨5.02%。截至发稿,该股报22.19美元/股,成交量49.6093万股,换手率0.58%,振幅6.34%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为0.83%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240710032218941f57e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240710032218941f57e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2448949937","title":"Syndax Pharmaceuticals, Inc.盘中异动 下午盘大幅拉升5.11%报21.58美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448949937","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448949937?lang=zh_cn&edition=full","pubTime":"2024-07-02 02:38","pubTimestamp":1719859139,"startTime":"0","endTime":"0","summary":"北京时间2024年07月02日02时38分,Syndax Pharmaceuticals, Inc.股票出现波动,股价急速上涨5.11%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.84%。其相关个股中,Senti Biosciences, Inc.、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Seastar Medical Holding Corporation涨幅较大,Senti Biosciences, Inc.、Geovax Labs, Inc.、Tonix Pharmaceuticals Holding Corp.较为活跃,换手率分别为765.20%、202.08%、122.99%,振幅较大的相关个股有Senti Biosciences, Inc.、Cingulate Inc.、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 ,振幅分别为101.49%、82.81%、56.57%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240702023859af900bc7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240702023859af900bc7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2445798214","title":"Syndax Pharmaceuticals, Inc.盘中异动 下午盘快速拉升5.03%报20.24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2445798214","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445798214?lang=zh_cn&edition=full","pubTime":"2024-06-22 01:36","pubTimestamp":1718991366,"startTime":"0","endTime":"0","summary":"北京时间2024年06月22日01时36分,Syndax Pharmaceuticals, Inc.股票出现异动,股价急速拉升5.03%。截至发稿,该股报20.24美元/股,成交量35.8686万股,换手率0.42%,振幅4.31%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.18%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240622013607941f02b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240622013607941f02b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2443562875","title":"Syndax Pharmaceuticals, Inc.盘中异动 快速上涨5.02%报20.29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2443562875","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443562875?lang=zh_cn&edition=full","pubTime":"2024-06-13 00:32","pubTimestamp":1718209940,"startTime":"0","endTime":"0","summary":"北京时间2024年06月13日00时32分,Syndax Pharmaceuticals, Inc.股票出现异动,股价大幅上涨5.02%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.37%。其相关个股中,Longeveron Inc.、Cingulate Inc C/Wts 10/12/2026 、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 涨幅较大,Longeveron Inc.、Tonix Pharmaceuticals Holding Corp.、Tracon Pharmaceuticals, Inc.较为活跃,换手率分别为413.09%、113.30%、34.63%,振幅较大的相关个股有Longeveron Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Nls Pharmaceutics Ltd C/Wts 02/02/2026,振幅分别为113.52%、85.53%、76.92%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240613003221af8d34eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240613003221af8d34eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2440484496","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘急速上涨5.14%报20.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2440484496","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440484496?lang=zh_cn&edition=full","pubTime":"2024-06-03 22:01","pubTimestamp":1717423303,"startTime":"0","endTime":"0","summary":"北京时间2024年06月03日22时01分,Syndax Pharmaceuticals, Inc.股票出现异动,股价大幅拉升5.14%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为1.05%。其相关个股中,Surrozen Inc C/Wts 01/08/2031 、Cingulate Inc C/Wts 10/12/2026 、Biocardia Inc C/Wts 06/08/2024涨幅较大,Bio-Path Holdings, Inc.、Scorpius Holdings, Inc.、Cyclacel Pharmaceuticals, Inc.较为活跃,换手率分别为2276.86%、70.14%、30.10%,振幅较大的相关个股有Bio-Path Holdings, Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 、Scorpius Holdings, Inc.,振幅分别为57.28%、44.05%、27.03%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240603220143af8ba942&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240603220143af8ba942&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2436945214","title":"Syndax Pharmaceuticals, Inc.2024财年第一财季实现净利润-72.40百万美元,同比减少76.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436945214","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436945214?lang=zh_cn&edition=full","pubTime":"2024-05-18 00:17","pubTimestamp":1715962658,"startTime":"0","endTime":"0","summary":"3月31日,Syndax Pharmaceuticals, Inc.公布财报,公告显示公司2024财年第一财季净利润为-72.40百万美元,同比减少76.03%;其中营业收入为0.00美元,每股基本收益为-0.85美元。机构评级:截至2024年3月31日,当前有12家机构对Syndax Pharmaceuticals, Inc.目标价做出预测,其中目标均价为34.17美元,其中最低目标价为23.00美元,最高目标价为45.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405180017418b13183b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405180017418b13183b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX"],"gpt_icon":0},{"id":"2434016312","title":"Stifel:维持Syndax Pharmaceuticals(SNDX.US)评级,由买入调整至买入评级, 目标价由39.00美元调整至40.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2434016312","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434016312?lang=zh_cn&edition=full","pubTime":"2024-05-09 22:15","pubTimestamp":1715264134,"startTime":"0","endTime":"0","summary":"Stifel:维持Syndax Pharmaceuticals(SNDX.US)评级,由买入调整至买入评级, 目标价由39.00美元调整至40.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050922153587e52a78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050922153587e52a78&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX"],"gpt_icon":0},{"id":"2433972145","title":"Syndax Pharmaceuticals, Inc.盘中异动 急速跳水5.00%报22.02美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2433972145","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433972145?lang=zh_cn&edition=full","pubTime":"2024-05-08 21:34","pubTimestamp":1715175247,"startTime":"0","endTime":"0","summary":"北京时间2024年05月08日21时34分,Syndax Pharmaceuticals, Inc.股票出现异动,股价大幅下挫5.00%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.16%。其相关个股中,Adaptive Biotechnologies Corporation、Repare Therapeutics Inc.、Cel-Sci Corporation涨幅较大,Enveric Biosciences, Inc.、Allarity Therapeutics, Inc.、Clearmind Medicine Inc.较为活跃,换手率分别为201.09%、28.22%、10.98%,振幅较大的相关个股有Y-Mabs Therapeutics, Inc.、Adaptive Biotechnologies Corporation、Veru Inc.,振幅分别为14.76%、13.50%、9.20%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405082134078ae8de47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405082134078ae8de47&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2432566971","title":"Syndax Pharmaceuticals Inc 预计每股亏损 98 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2432566971","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432566971?lang=zh_cn&edition=full","pubTime":"2024-05-03 20:33","pubTimestamp":1714739597,"startTime":"0","endTime":"0","summary":" * Syndax Pharmaceuticals Inc 将于5月8日公布截至2024年3月31日的财报,预计该公司的季度收入将保持不变。* * LSEG分析师对Syndax Pharmaceuticals Inc的平均预期是每股亏损98美分。* 华尔街对 Syndax Pharmaceuticals Inc 的 12 个月目标价中值为 35.00 美元,高于其上一交易日 21.86 美元的收盘价。5月3日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0},{"id":"2432333766","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.02%报22.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432333766","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432333766?lang=zh_cn&edition=full","pubTime":"2024-05-02 02:45","pubTimestamp":1714589106,"startTime":"0","endTime":"0","summary":"北京时间2024年05月02日02时45分,Syndax Pharmaceuticals, Inc.股票出现波动,股价快速拉升5.02%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为1.91%。其相关个股中,Cytomx Therapeutics, Inc.、Cyclacel Pharmaceuticals, Inc.、Aptevo Therapeutics Inc.涨幅较大,Palisade Bio, Inc.、Cyclacel Pharmaceuticals, Inc.、Cytomx Therapeutics, Inc.较为活跃,换手率分别为1407.62%、1153.26%、261.77%,振幅较大的相关个股有Cytomx Therapeutics, Inc.、Cyclacel Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 ,振幅分别为188.34%、99.53%、77.43%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405020245067a57df51&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405020245067a57df51&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2430003276","title":"HC Wainwright & Co.:重申Syndax Pharmaceuticals(SNDX.US)评级,由买入调整至买入评级, 目标价41.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2430003276","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430003276?lang=zh_cn&edition=full","pubTime":"2024-04-26 19:45","pubTimestamp":1714131917,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.:重申Syndax Pharmaceuticals(SNDX.US)评级,由买入调整至买入评级, 目标价41.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042619452187b37d73&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042619452187b37d73&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX"],"gpt_icon":0},{"id":"2426410129","title":"Syndax Pharmaceuticals, Inc.盘中异动 大幅跳水5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426410129","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2426410129?lang=zh_cn&edition=full","pubTime":"2024-04-11 00:30","pubTimestamp":1712766644,"startTime":"0","endTime":"0","summary":"北京时间2024年04月11日00时30分,Syndax Pharmaceuticals, Inc.股票出现异动,股价大幅跳水5.09%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为1.25%。其相关个股中,Adial Pharmaceuticals, Inc、Jaguar Health, Inc.、Orgenesis Inc.涨幅较大,Adial Pharmaceuticals, Inc、Silo Pharma, Inc.、Jaguar Health, Inc.较为活跃,换手率分别为1915.38%、76.53%、51.56%,振幅较大的相关个股有Adial Pharmaceuticals, Inc、Orgenesis Inc.、Nutriband Inc C/Wts ,振幅分别为87.61%、74.23%、52.44%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404110030447a51ed0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404110030447a51ed0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2420798966","title":"美国研究综述-迪克体育用品、Nvidia、PVH","url":"https://stock-news.laohu8.com/highlight/detail?id=2420798966","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2420798966?lang=zh_cn&edition=full","pubTime":"2024-03-20 15:14","pubTimestamp":1710918896,"startTime":"0","endTime":"0","summary":" 路透社3月20日 - 华尔街证券分析师周三调整了对迪克体育用品公司、英伟达和 PVH 等几家美国上市公司的评级和目标价。股票条目按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTDR","BK4525","BK4588","BK4505","HLT","LU0170899867.USD","DCPH","GOCO","BK4527","BK4503","RIOT","CAL","CSCO","IE00BMPRXN33.USD","RCM","SAIC","BK4543","LU0444971666.USD","PTCT","SMPL","TNYA","CNM","LU0053671581.USD","LU0731783394.SGD","BRO","DKS","SNDX","LU0072462426.USD","BK4023","IE00BWXC8680.SGD","PVH","RLMD","RAIL","SG9999002224.SGD","TRML","BK4216","CRNX","HQY","PLNT","BBIO","NVDA","SG9999002232.USD","BK4213","LU0889565916.HKD","HPP","LU0238689110.USD","LU1430594728.SGD","BK4139","BK4212","ASO"],"gpt_icon":0},{"id":"2420092084","title":"Syndax Pharmaceuticals, Inc.盘中异动 临近午盘快速下跌5.06%报22.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2420092084","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2420092084?lang=zh_cn&edition=full","pubTime":"2024-03-18 23:31","pubTimestamp":1710775884,"startTime":"0","endTime":"0","summary":"北京时间2024年03月18日23时31分,Syndax Pharmaceuticals, Inc.股票出现异动,股价大幅跳水5.06%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.52%。其相关个股中,Immuneering Corporation、Celularity Inc C/Wts 16/07/2026 、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 涨幅较大,Zyversa Therapeutics, Inc.、Immuneering Corporation、Jaguar Health, Inc.较为活跃,换手率分别为133.93%、34.50%、21.55%,振幅较大的相关个股有Artelo Biosciences Inc C/Wts 20/06/2024 、Immuneering Corporation、Tc Biopharm Plc C/Wts 10/02/2028 ,振幅分别为443.52%、67.02%、50.00%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240318233125791b385e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240318233125791b385e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2419872931","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大跌5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2419872931","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2419872931?lang=zh_cn&edition=full","pubTime":"2024-03-15 02:57","pubTimestamp":1710442621,"startTime":"0","endTime":"0","summary":"北京时间2024年03月15日02时57分,Syndax Pharmaceuticals, Inc.股票出现波动,股价快速下跌5.09%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为0.95%。其相关个股中,Revolution Medicines Inc C/Wts 17/12/2026 、Psyence Biomedical Ltd.、知临集团涨幅较大,知临集团、Psyence Biomedical Ltd.、Novabay Pharmaceuticals, Inc.较为活跃,换手率分别为809.79%、220.36%、183.94%,振幅较大的相关个股有Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Psyence Biomedical Ltd.、知临集团,振幅分别为110.40%、87.49%、76.91%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240315025701791a8788&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240315025701791a8788&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2416964990","title":"Syndax Pharmaceuticals, Inc.2023财年实现净利润-2.09亿美元,同比减少40.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416964990","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2416964990?lang=zh_cn&edition=full","pubTime":"2024-03-03 00:27","pubTimestamp":1709396833,"startTime":"0","endTime":"0","summary":"12月31日,Syndax Pharmaceuticals, Inc.公布财报,公告显示公司2023财年净利润为-2.09亿美元,同比减少40.27%;其中营业收入为0.00美元,每股基本收益为-2.98美元。机构评级:截至2023年12月31日,当前有11家机构对Syndax Pharmaceuticals, Inc.目标价做出预测,其中目标均价为35.27美元,其中最低目标价为23.00美元,最高目标价为45.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030300271687dcef3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030300271687dcef3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX"],"gpt_icon":0},{"id":"2414852734","title":"Syndax Pharmaceuticals Inc盘中异动 临近收盘急速上涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2414852734","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2414852734?lang=zh_cn&edition=full","pubTime":"2024-02-27 04:43","pubTimestamp":1708980195,"startTime":"0","endTime":"0","summary":"北京时间2024年02月27日04时43分,Syndax Pharmaceuticals Inc股票出现异动,股价急速拉升5.02%。Syndax Pharmaceuticals Inc股票所在的生物技术行业中,整体涨幅为0.76%。其相关个股中,Zyversa Therapeutics Inc、Sab Biotherapeutics Inc C/Wts 22/10/2026 、Krystal Biotech Inc涨幅较大,Zyversa Therapeutics Inc、Ocean Biomedical Inc、Neubase Therapeutics Inc较为活跃,换手率分别为1847.57%、264.81%、93.87%,振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Zyversa Therapeutics Inc、Ocean Biomedical Inc,振幅分别为209.86%、161.05%、85.99%。Syndax Pharmaceuticals Inc公司简介:Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022704431587e7335b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022704431587e7335b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2413729749","title":"Syndax Pharmaceuticals Inc 预计每股亏损 99 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2413729749","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2413729749?lang=zh_cn&edition=full","pubTime":"2024-02-24 09:02","pubTimestamp":1708736530,"startTime":"0","endTime":"0","summary":" * Syndax Pharmaceuticals Inc 将于2月27日公布截至2023年12月31日的财报,预计季度营收将保持不变。* * LSEG分析师对Syndax Pharmaceuticals Inc的平均预期是每股亏损99美分。* 华尔街对 Syndax Pharmaceuticals Inc 的 12 个月目标价中位数为 35.50 美元,高于其上次收盘价 23.13 美元。2月24日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0},{"id":"2411158350","title":"Syndax Pharmaceuticals Inc盘中异动 股价大跌5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2411158350","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2411158350?lang=zh_cn&edition=full","pubTime":"2024-02-13 22:31","pubTimestamp":1707834660,"startTime":"0","endTime":"0","summary":"北京时间2024年02月13日22时31分,Syndax Pharmaceuticals Inc股票出现波动,股价急速下挫5.16%。Syndax Pharmaceuticals Inc股票所在的生物技术行业中,整体跌幅为0.46%。其相关个股中,Biodexa Pharmaceuticals Plc、Bioxcel Therapeutics Inc、Adial Pharmaceuticals Inc涨幅较大,Biodexa Pharmaceuticals Plc、Adial Pharmaceuticals Inc、Kintara Therapeutics Inc较为活跃,换手率分别为292.05%、79.75%、29.32%,振幅较大的相关个股有Lisata Therapeutics Inc、Indaptus Therapeutics Inc、Nuvalent Inc,振幅分别为6.62%、6.51%、6.19%。Syndax Pharmaceuticals Inc公司简介:Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240213223101861d5067&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240213223101861d5067&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.syndax.com","stockEarnings":[{"period":"1week","weight":0.0992},{"period":"1month","weight":0.2337},{"period":"3month","weight":0.1962},{"period":"6month","weight":0.1642},{"period":"1year","weight":0.1502},{"period":"ytd","weight":0.1481}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1285},{"period":"6month","weight":0.1855},{"period":"1year","weight":0.2529},{"period":"ytd","weight":0.1884}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Syndax Pharmaceuticals, Inc.于2005年10月11日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司,正在开发癌症疗法的创新管道。该公司正在开发revumenib,这是一种有效的、选择性的、menin-MLL结合相互作用的小分子抑制剂,用于治疗KMT2A重排或KMT2AR,也称为混合谱系白血病重排或MLLR,包括急性淋巴细胞白血病或ALL在内的急性白血病,以及急性髓细胞白血病或AML,以及necleophosmin 1,也称为NPM1,突变AML。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.044305},{"month":2,"riseRate":0.625,"avgChangeRate":0.07889},{"month":3,"riseRate":0.625,"avgChangeRate":0.084467},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.000613},{"month":5,"riseRate":0.444444,"avgChangeRate":0.006686},{"month":6,"riseRate":0.555556,"avgChangeRate":0.008456},{"month":7,"riseRate":0.555556,"avgChangeRate":0.022903},{"month":8,"riseRate":0.625,"avgChangeRate":0.063716},{"month":9,"riseRate":0.625,"avgChangeRate":-0.024123},{"month":10,"riseRate":0.25,"avgChangeRate":-0.081003},{"month":11,"riseRate":0.625,"avgChangeRate":0.015744},{"month":12,"riseRate":0.5,"avgChangeRate":0.063584}],"exchange":"NASDAQ","name":"Syndax Pharmaceuticals, Inc. ","nameEN":"Syndax Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Syndax Pharmaceuticals, Inc. (SNDX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Syndax Pharmaceuticals, Inc. (SNDX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Syndax Pharmaceuticals, Inc. ,SNDX,Syndax Pharmaceuticals, Inc. 股票,Syndax Pharmaceuticals, Inc. 股票老虎,Syndax Pharmaceuticals, Inc. 股票老虎国际,Syndax Pharmaceuticals, Inc. 行情,Syndax Pharmaceuticals, Inc. 股票行情,Syndax Pharmaceuticals, Inc. 股价,Syndax Pharmaceuticals, Inc. 股市,Syndax Pharmaceuticals, Inc. 股票价格,Syndax Pharmaceuticals, Inc. 股票交易,Syndax Pharmaceuticals, Inc. 股票购买,Syndax Pharmaceuticals, Inc. 股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Syndax Pharmaceuticals, Inc. (SNDX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Syndax Pharmaceuticals, Inc. (SNDX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}